Urate, blood pressure and cardiovascular disease: updated evidence from Mendelian randomization and meta-analysis of clinical trials

Gill *et al*. Urate, blood pressure and cardiovascular disease

Dipender Gill BMBCh PhD[1]*, Alan C. Cameron MBChB PhD[2]*, Stephen Burgess PhD[3,4], Xue Li PhD[5], Daniel J. Doherty MBChB[2], Ville Karhunen MSc[1], Azmil H Abdul-Rahim MBChB MD[6], Martin Taylor-Rowan PhD[2], Verena Zuber PhD[1,3], Philip S. Tsao PhD[7,8], Derek Klarin MD[9-12], VA Million Veteran Program, Evangelos Evangelou PhD[1,13], Paul Elliott FMedSci[1,14-17], Scott M. Damrauer MD[18,19], Terence J Quinn MBChB[2], Abbas Dehghan MD PhD[1,14,15], Evropi Theodoratou PhD[5,20]†, Jesse Dawson MBChB PhD[2]†, Ioanna Tzoulaki PhD[1,13-15]†

*These authors contributed equally and are joint first

†These authors contributed equally and are joint last

Affiliations

[1]Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

[2]Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK.

[3]MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK.

[4]Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

[5]Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK.

6Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK.

[7]VA Palo Alto Health Care System, California, USA.

[8]Department of Medicine, Stanford University School of Medicine, California, USA.

[9]Malcom Randall VA Medical Center, Gainesville, Florida, USA.

[10]Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Massachusetts, USA.

[11]Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Massachusetts, USA.

[12]Division of Vascular Surgery and Endovascular Therapy, University of Florida School of Medicine, Gainesville, Florida, USA.

[13]Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece.

[14]MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, UK.

[15]UK Dementia Research Institute at Imperial College London, London, UK.

[16]Imperial Biomedical Research Centre, Imperial College London and Imperial College NHS Healthcare Trust, London, UK.

[17]Health Data Research UK-London, London, UK.

[18]Corporal Michael J. Crescenz VA Medical Center, Philadelphia, USA.

[19]Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia,

USA.

[20]Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of

Edinburgh, Edinburgh, United Kingdom.

Corresponding author

Dr Dipender Gill

Department of Epidemiology and Biostatistics, School of Public Health, Medical School Building, St

Mary's Hospital, Imperial College London, United Kingdom, W2 1PG

Telephone: +44 (0) 7904843810

Fax: +44 (0) 20 3313 8223

E-mail: dipender.gill@imperial.ac.uk

Total word count: 4,845

Abstract (250 words)

Aims: To investigate the effect of serum urate on blood pressure and cardiovascular disease (CVD) risk by updating evidence from Mendelian randomization (MR) analysis and meta-analysis of randomized controlled trials (RCTs).

Methods and Results: Using recently available data from the Million Veterans Program and UK Biobank, the main MR analyses showed that every 1-standard deviation increase in genetically predicted serum urate was associated with an increased risk of coronary heart disease (odds ratio 1.19, 95% confidence interval 1.10-1.30, $P=4\times10^{-5}$), peripheral artery disease (1.12, 95%CI 1.03 to 1.21, $P=9\times10^{-3}$), and stroke (1.11, 95%CI 1.05 to 1.18, $P=2\times10^{-4}$). In MR mediation analyses, SBP was estimated to mediate approximately one third the effect of urate on CVD risk. Systematic review and meta-analysis of RCTs showed a favorable effect of urate-lowering treatment on SBP (mean difference -2.55mmHg, 95%CI -4.06 to -1.05, $P=1\times10^{-3}$) and major adverse cardiovascular events (MACE) in those with previous CVD (OR 0.40, 95%CI 0.22 to 0.73, $P=3\times10^{-3}$), but no significant effect on MACE in all individuals (OR 0.73, 95%CI 0.48 to 1.09, $P=0.12$).

Conclusion: MR and clinical trial data support an effect of higher serum urate on increasing blood pressure, which may mediate a consequent effect on CVD risk. High-quality trials are necessary to provide definitive evidence on the specific clinical contexts where urate-lowering may be of cardiovascular benefit.

Key words: urate, cardiovascular disease, blood pressure, Mendelian randomization, systematic review.

1 Introduction

Urate is a breakdown product of purine metabolism. Its raised levels have been associated with a

number of adverse health outcomes including gout, hypertension and cardiovascular disease (CVD)

(1). However, it remains unclear whether these associations represent causal effects (2, 3). The

relationship between serum urate, obesity, diet and other cardiovascular risk factors raises

considerable potential for confounding and reverse causation (4).

Pre-clinical studies support a causal role for urate in hypertension (5). Randomized controlled trial

(RCT) data have shown that both allopurinol and probenecid reduce systolic blood pressure (SBP) in

hyperuricemic adolescents (1, 6, 7). Pooling of all available trial data can offer more precise effect

estimates for the effect of urate-lowering therapy on blood pressure (8). As elevated blood pressure

is a risk factor for CVD, it is important to clarify any role of SBP in mediating an effect of urate on

cardiovascular outcomes.

The genetic determinants of serum urate levels have been increasingly well-characterized (4). This

has made it possible to identify better instruments for Mendelian randomization (MR) analyses

investigating the effect of genetically predicted serum urate on cardiovascular outcomes than in

previous efforts (3, 9-11). The use of variants randomly allocated at conception to proxy the effect of

modifying serum urate means that MR is less susceptible to the environmental confounding,

measurement error and reverse causation bias that can limit causal inference in traditional

epidemiological approaches.

The aim of the current study was to perform MR analyses investigating the effect of genetically

predicted urate levels on SBP and CVD risk using contemporary data, and compare findings with

results obtained from updated systematic review and meta-analysis of urate-lowering RCTs.

Methods

Two-sample Mendelian randomization

The MR analyses have been reported as per the STROBE-MR guidelines (Supplementary Checklist 1)

(12).

Genetic association estimates

Genetic association estimates for serum urate in two-sample MR were obtained by using PLINK

software to meta-analyze summary data from GWAS analyses of 110,347 European-ancestry

individuals and 343,836 White British UK Biobank participants respectively (13-15). Urate estimates

in MR analyses are provided per 1-standard deviation (SD), which corresponds to 80.3µmol/L. For

consideration of SBP as a mediator in the two-sample multivariable MR, genetic association

estimates were obtained from a GWAS of 317,195 White British UK Biobank participants, where SBP

was measured using automated readings with correction made for any anti-hypertensive drug use

by adding 10mmHg to the measured reading (16). In contrast, when investigating SBP as an

outcome, genetic association estimates were obtained from the International Consortium for Blood

Pressure (ICBP) GWAS analysis of 287,245 European-ancestry individuals (excluding UK Biobank

participants) (17). A different population was considered when studying SBP as an outcome to avoid

overlap with the UK Biobank participants used to obtain genetic association estimates for urate, as

this can bias MR estimates (18). SBP estimates are provided per 1-SD increase, which corresponds to

18.6mmHg. Genetic association estimates for CHD were obtained from the CARDIoGRAMplusC4D

Consortium 1000G multi-ethnic GWAS (77% European-ancestry) of 60,801 cases and 123,504

controls, with a broad and inclusive definition of CHD applied (19). Genetic association estimates for

PAD were obtained from the Million Veterans Program (MVP) multi-ethnic (72% European-ancestry)

GWAS of 31,307 cases and 211,753 controls, with case definitions made using hospital diagnosis and

procedure codes (20). Genetic association estimates for stroke were obtained from the

MEGASTROKE multi-ethnic (86% European-ancestry) GWAS of 67,162 cases and 454,450 controls

(21), with the stroke definition including both ischemic and hemorrhagic etiologies.

Genetic variants used as instruments

Genetic instruments for the two-sample MR were identified as single-nucleotide polymorphisms

(SNPs) that were associated with urate (or SBP, in mediation analyses) at genome-wide significance

(P<5x10^{-8}) and were in pair-wise linkage disequilibrium (LD) with r^2<0.001. Clumping was performed

using the TwoSampleMR package of R (22). For univariable MR, instrument strength was estimated

using the F-statistic, with variance in the exposure explained assessed using the R^2 value (23).

Statistical analysis

In all analyses, SNPs were aligned by their effect alleles and no additional consideration was made

for palindromic variants. Two-sample MR analyses were performed to investigate the effect of

genetically predicted serum urate on CHD, PAD, stroke and SBP respectively. A Bonferroni threshold

(P<0.01) that corrected for multiple testing related to the four outcomes was used to ascertain

statistical significance in the main analysis. Inverse-variance weighted MR was used in the main

analysis, with the simple median (24), contamination-mixture method (25), Egger (26), PRESSO (27)

and multivariable MR (28) (only for CVD outcomes) sensitivity analyses used to explore the

robustness of the findings to potential pleiotropy of the genetic variants. Given the previously

demonstrated overlap in the genetic determinants of urate with other metabolic traits (4), the

multivariable MR sensitivity analysis adjusted for genetic associations of the instruments with body

mass index (BMI), estimated glomerular filtration rate, type 2 diabetes mellitus, serum low-density

lipoprotein cholesterol, serum high-density lipoprotein cholesterol and serum triglycerides together

in the same model. Such multivariable MR was not performed when considering SBP as an outcome,

due to population overlap with the cohorts used to obtain genetic association estimates for the

metabolic exposures (18). In MR mediation analyses, multivariable MR was applied in the two-

sample setting to adjust for the genetic association of the instruments with SBP, and network MR

was used to estimate the proportion of the total effect of urate on each cardiovascular outcome that

is mediated through SBP (29). Standard errors were estimated using the propagation of error

method. Further details on these analyses are provided in the Supplementary Methods.

Genetic association estimates, instruments and statistical analyses for the one-sample MR are

detailed in the Supplementary Methods.

Systematic review and meta-analysis of randomized controlled trials

The systematic review was conducted in accordance with the recommendations from the Preferred

Reporting Items for Systematic Reviews and Meta-analyse (PRISMA) statement (Supplementary

Checklist 2) (30). The study protocol was registered and published in the International Prospective

Register of Systematic Reviews (PROSPERO: CRD42020164589).

Inclusion and exclusion criteria

RCTs of pharmacological urate-lowering versus placebo or no treatment of duration ≥28 days in

patients ≥18 years of age were eligible. Studies with co-intervention that was inconsistent between

intervention and control groups, or with mixed experimental groups were excluded.

Data sources and searches

We conducted a systematic search of multidisciplinary databases across four electronic platforms:

Medline (OVID), EMBASE (OVID), Web of Science (Thomson Reuters) and Cochrane Library

(Cochrane). Studies published from 1 January 2016 to 30 September 2019 were considered. The

literature search terms matched those used in a previous systematic review (Supplementary

Methods) (7). No language restrictions were applied. Reference lists of retrieved articles were

reviewed to identify additional relevant articles. Data were included from studies in previous

systematic reviews investigating the effects of urate lowering therapy on SBP (searches until 29 June

2016) (8), and CVD (searches until 30 December 2016) (7).

Data extraction

Study details and results were extracted using a pre-designed template. In the case of cross-over

trials, only data from the first study period (before cross-over) were used. Risk of bias was assessed

in accordance with the Cochrane guidelines (31). All aspects of database search, study selection,

data extraction and risk of bias assessment were performed independently by two investigators

(ACC and DJD), with arbitration to a third investigator (AHA-R) as necessary.

Outcomes

The outcomes considered in systematic review and meta-analysis of RCTs were SBP and risk of major

adverse cardiovascular event (MACE; cardiovascular death, non-fatal myocardial infarction, unstable

angina requiring urgent revascularization, or non-fatal stroke). In secondary analysis, we also

considered MACE in patients with prior CVD, as this would likely represent a higher risk population

with greater statistical power.

Statistical analysis

Analysis of extracted data was based on modified intention-to-treat (considering patients who

received at least one dose of the allocated treatment) or intention-to-treat results. If not reported,

the mean change in SBP pre- and post-treatment was calculated and the SD was imputed using the

propagation of error method using a correlation coefficient that was derived from the largest study

in the meta-analysis that reported SD for SBP values at baseline, at end of the study and for the

change in SBP (31, 32). The measure of effect size was the difference in mean SBP, defined as the

mean difference between patients treated with urate lowering therapy versus control. A negative

value of the difference in mean SBP indicates a greater reduction of SBP in the urate lowering

therapy group as compared to the control group. Overall CVD risk estimates are described in terms

of odds-ratio (OR).

Random-effects inverse-variance weighted meta-analysis was used to pool estimates from different

studies, and study heterogeneity was assessed using the I-squared (I^2) statistic. Sensitivity analyses

were conducted including only studies at low risk of bias. For the analysis considering SBP as an

outcome, meta-regression was performed to assess the effect of baseline SBP on treatment

response. Analyses were conducted using Comprehensive Meta-Analysis software version 3 (Biostat,

USA).

Ethical approval, data availability and reporting

All data used in this work are either publicly accessible or available on request from their original

studies, which obtained appropriate patient consent and ethical approval. The UK Biobank data were

accessed through application 236. All results generated in this work are presented in either the

manuscript or its supplementary files.

Results

Mendelian randomization

The instruments for urate that were used in the two-sample MR are presented in Supplementary

Table 2. The main IVW MR showed that higher genetically predicted serum urate levels were

associated with an increased risk of CHD, with odds ratio (OR) per 1-SD increase in genetically

predicted urate 1.19, 95% confidence interval (95%CI) 1.10-1.30, $P=4\times10^{-5}$. Consistent results were

obtained in all MR sensitivity analyses except MR-Egger, which had wide 95%CIs (Figure 1). Higher

genetically predicted serum urate was also associated with increased risk of both PAD (OR 1.12,

95%CI 1.03-1.21, $P=9\times10^{-3}$) and stroke (OR 1.11, 95%CI 1.05-1.18, $P=2\times10^{-4}$) in the main IVW analysis,

with similar results obtained in all MR sensitivity analyses except MR-Egger, which again had wide

95%CIs (Figure 1). For the multivariable MR adjusting for genetic confounding through BMI,

estimated glomerular filtration rate, type 2 diabetes and lipid traits, direct effects of these exposures

on risk of the respective CVD outcomes are presented in Supplementary Table 3. Considering SBP,

the main IVW and sensitivity MR analyses all provided supporting evidence of a causal effect of

serum urate (IVW estimate in SD units per 1-SD increase in genetically predicted urate 0.09, 95%CI

0.05-0.12, $P=6\times10^{-7}$; Figure 2). Scatter plots depicting the association of the instrument variants with

serum urate and the respective outcomes are presented in Supplementary Figures 1-4.

Performing multivariable MR to adjust for genetically predicted SBP showed attenuation of the urate

effect estimates for the CVD outcomes as compared to the main IVW univariable MR (Figure 3),

supporting that part of the effect of urate on these outcomes is mediated through SBP. Network MR

mediation analysis quantified this as 29% (95%CI 9%-48%) for CHD, 44% (95%CI 5%-83%) for PAD

and 45% (95%CI 14%-76%) for stroke. For CHD there remained evidence of a direct effect of urate

even after adjusting for SBP (OR 1.13, 95%CI 1.03-1.23, P=0.01). In contrast for PAD and stroke,

although the estimate for the direct effect of urate that is not mediated through SBP was positive,

the confidence interval crossed the null and the results were not statistically significant (PAD OR

1.08, 95%CI 1.00-1.17, P=0.07; stroke OR 1.06, 95%CI 0.99-1.12, P=0.10). Direct effects of SBP on the

outcomes after adjusting for genetically predicted serum urate are presented in Supplementary

Table 4.

The results of the one-sample MR analysis were consistent with the above-mentioned two-sample

MR analysis and are detailed in the Supplementary Results, Supplementary Tables 5-8 and

Supplementary Figure 5.

Systematic review and meta-analysis of randomized controlled trials

In total, 95 studies were eligible for the systematic review and meta-analysis. Regarding the updated

searches (1 January 2016 to 30 September 2019), 5,353 records were screened, 30 full texts were

assessed for eligibility and 13 studies were identified that fulfilled the eligibility criteria

(Supplementary Figure 6). Characteristics of included studies that were identified in the updated

search are presented in Supplementary Table 9.

The primary analysis of effects on SBP included 15 studies (Supplementary Figure 7). There was

heterogeneity between these studies (I^2 89%), which was mostly attributable to one study

considering renal dialysis patients (Supplementary Figure 7) (33). Excluding this study, subjects

treated with urate-lowering therapy had greater reduction in SBP than subjects in the control group

(mean difference in SBP -2.55, 95%CI -4.06 to -1.05, P=1x10^{-3}, I^2 43%) (Figure 4). The analysis of

MACE risk in all patients considered 88 studies, of which 24 had events (Figure 5), and the analysis of

MACE risk in patients with prior cardiovascular events considered 10 studies, of which 7 had events

(Figure 6). Urate-lowering therapy was not significantly associated with risk of MACE in all patients

(OR 0.73, 95%CI 0.48 to 1.09, P=0.12, I^2 0%), but was significantly associated with reduction in risk of

MACE in patients with a prior cardiovascular event (OR 0.40, 95%CI 0.22 to 0.73, P=3x10^{-3}, I^2 0%).

Risk of bias was low in 23 of the 95 included studies (Supplementary Table 10). Risk of bias was low

in 4 out of the 15 studies investigating effects on SBP, 20 out of the 24 studies investigating MACE in

all patients, and 4 out of the 7 studies investigating MACE in patients with a prior cardiovascular

event. In sensitivity analyses including only studies at low risk bias, urate lowering therapy was

associated with greater SBP lowering compared to control (mean difference in SBP -2.89, 95%CI -

5.37 to -0.41, P=0.02, I^2 49%; Supplementary Figure 8), but was not significantly associated with risk

of MACE in all patients (OR 0.64, 95%CI 0.28 to 1.46, P=0.29, I^2 0%; Supplementary Figure 9) or in

patients with a prior cardiovascular event (OR 0.59, 95% CI 0.18 to 1.91, P=0.38, I^2 0%;

Supplementary Figure 10). Meta-regression analysis demonstrated no effect of baseline SBP on

treatment response to urate lowering therapy (coefficient -0.01, 95% CI -0.19 to 0.17, P=0.92;

Supplementary Figure 11).

Discussion

We used a comprehensive framework of MR methodologies to perform detailed investigation into

the association of genetically predicted serum urate with CVD outcomes, and replicated findings in

the independent UK Biobank population. The MR analyses identified consistent evidence of an effect

of higher genetically predicted serum urate levels on risk of CVD and SBP. Performing multivariable

MR to adjust for genetic association with SBP attenuated the estimates for the CVD outcomes to

support that at least some of the effect of urate may be mediated through raised blood pressure.

Updated systematic review and meta-analysis of RCT data similarly showed a favorable effect of

urate-lowering treatment on SBP, with some evidence to also support a protective effect on MACE

risk in individuals with prior CVD, but not in all individuals.

Hyperuricemia has been postulated to cause endothelial dysfunction by increasing oxidative stress

(1), and this could directly increase risk of CVD through effects on the vascular endothelium (1). In an

animal model where hyperuricemia was induced using a uricase inhibitor, hypertension followed

after three weeks while controls remained normotensive (5), thus representing a second mechanism

by which urate can increase risk of CVD. The results of the Febuxostat and Allopurinol Streamlined

Trial (FAST) and the Allopurinol and cardiovascular outcomes in patients with ischemic heart disease

(ALL-HEART) trials will help provide further insight on potential re-purposing of existing urate-

lowering agents for CVD prevention (34, 35). Allopurinol could represent an inexpensive, safe and

well-tolerated drug for reducing cardiovascular risk (36).

Our current study has several strengths. We triangulate evidence across MR analyses and RCT data

to provide consistent evidence for a role of serum urate in increasing SBP and potentially also

increasing CVD risk. Our analyses identify a possible mediating role of SBP in the pathway from

serum urate to CVD risk. In contrast, previous MR studies have considered associations of the

genetic instruments for urate with blood pressure as representing genetic confounding (3, 9-11).

Exclusion of such variants or adjustment for their genetic association with blood pressure traits, as

was done in these studies (3, 9-11), would obscure any true causal effect of genetically predicted

urate on cardiovascular disease risk. Our present MR analysis also incorporated more powerful

instruments for serum urate than were available previously. The variants used as instruments in our

one-sample MR analysis of UK Biobank participants explained approximately 7.7% of the variance in

serum urate (4), in contrast to the 5.3% explained when selecting instrument variants from the

previous largest published GWAS of serum urate (13). Similarly, our systematic review and meta-

analysis of RCTs updated evidence from previous efforts to consider an additional 13 studies (7, 8).

Our work also has limitations. The MR approach makes a series of modelling assumptions, and in

particular requires that the genetic variants used as instruments do not affect the considered

outcomes through pathways that are independent of urate. While this can never be completely

excluded, we performed a range of MR sensitivity analyses that make distinct assumptions on the

presence of pleiotropic variants and generally found consistent estimates. The MR-Egger method

generated wide 95%CIs in all analyses and was likely of limited reliability due to the strength of the

urate instruments being correlated to their direct effects on the CVD outcomes under consideration

(4, 37). The majority (71 out of 94) RCTs considered in our meta-analysis had a high or undetermined

risk of bias and there was heterogeneity in the results of RCTs measuring change in SBP following

urate-lowering therapy, possibly related to study design, in turn limiting the strength of conclusions

that can be drawn. Finally, we investigated SBP in mediating the effect of urate on CVD outcomes,

rather than diastolic blood pressure. These two traits are highly genetically and phenotypically

correlated (17), and it follows that a similar mediating role may be found for diastolic blood

pressure.

To summarize, we have found consistent MR and RCT evidence for an effect of higher serum urate

levels on increasing SBP, with further evidence also supporting a potential effect on risk of CVD.

High-quality trial data are now necessary to provide definitive evidence on the specific clinical

contexts where urate-lowering may be of cardiovascular benefit, with some large-scale studies

already underway (34, 35).

Contributors

DG, JD, ACC, ET and IT designed the study. DG, XL, ACC, DD, AHA-R and MT-R had full access to the data and performed the analysis. All authors interpreted the results. DG, JD, ACC and IT drafted the manuscript. All authors critically revised the manuscript for intellectual content. All authors approved the submitted version and are accountable for the integrity of the work.

Sources of Funding

This work was supported by funding from the US Department of Veterans Affairs Office of Research and Development, Million Veteran Program Grant MVP003 (I01-BX003362). This publication does not represent the views of the Department of Veterans Affairs of the US Government. DG is funded by the Wellcome 4i Clinical PhD Program at Imperial College London (203928/Z/16/Z). VK is funded by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant (721567). PE acknowledges support from the Medical Research Council (MR/S019669/1), the National Institute for Health Research Imperial Biomedical Research Centre, Imperial College London (RDF03), the UK Dementia Research Institute (DRI) at Imperial College London funded by UK DRI Ltd (funded by Medical Research Council, Alzheimer's Society, Alzheimer's Research UK), and Health Data Research (HDR) UK London funded by HDR UK Ltd (funded by a consortium led by the Medical Research Council 1004231). SMD was supported by the Department of Veterans Affairs Office of Research and Development (IK2-CX001780). ET is funded by a Cancer Research UK Career Development Fellowship (C31250/A22804). The MEGASTROKE project received funding from sources specified at http://www.megastroke.org/acknowledgments.html. Details of all MEGASTROKE authors are available at http://www.megastroke.org/authors.html.

Acknowledgements

The authors acknowledge the contributors of the data used in this work: CARDIoGRAMplusC4D, CKDGen, DIAGRAM, Genetic Investigation of ANthropometric Traits, Global Lipids Genetics Consortium, International Consortium for Blood Pressure, MEGASTROKE, Million Veterans Program and UK Biobank.

Disclosures

DG is employed part-time by Novo Nordisk. JD and TQ have received charitable research income to conduct clinical trials of allopurinol use in people with stroke. The remaining authors have no conflicts of interest to declare.

References

1.   Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811-21.

2.   Li X, Meng X, Timofeeva M, Tzoulaki I, Tsilidis KK, Ioannidis JP, et al. Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. BMJ. 2017;357:j2376.

3.   Li X, Meng X, He Y, Spiliopoulou A, Timofeeva M, Wei WQ, et al. Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization study. PLoS Med. 2019;16(10):e1002937.

4.   Tin A, Marten J, Halperin Kuhns VL, Li Y, Wuttke M, Kirsten H, et al. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nat Genet. 2019.

5.   Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101-6.

6.   Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924-32.

7.   Bredemeier M, Lopes LM, Eisenreich MA, Hickmann S, Bongiorno GK, d'Avila R, et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2018;18(1):24.

8.   Qu LH, Jiang H, Chen JH. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. Ann Med. 2017;49(2):142-56.

9.   Keenan T, Zhao W, Rasheed A, Ho WK, Malik R, Felix JF, et al. Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study. J Am Coll Cardiol. 2016;67(4):407-16.

10.   Efstathiadou A, Gill D, McGrane F, Quinn T, Dawson J. Genetically Determined Uric Acid and

the Risk of Cardiovascular and Neurovascular Diseases: A Mendelian Randomization Study of

Outcomes Investigated in Randomized Trials. J Am Heart Assoc. 2019;8(17):e012738.

11.   White J, Sofat R, Hemani G, Shah T, Engmann J, Dale C, et al. Plasma urate concentration and

risk of coronary heart disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol.

2016;4(4):327-36.

12.   Davey Smith G, Davies NM, Dimou N, Egger M, Gallo V, Golub R, et al. STROBE-MR:

Guidelines for strengthening the reporting of Mendelian randomization studies.

https://doi.org/10.7287/peerj.preprints.27857v1. PeerJ Preprints. 2019;7:e27857v1.

13.   Kottgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, et al. Genome-wide

association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet.

2013;45(2):145-54.

14.   Neale Lab. Accessed 2019 January 16. Rapid GWAS of thousands of phenotypes for 337,000

samples in the UK Biobank 2018. http://www.nealelab.is/blog/2017/7/19/rapid-gwas-of-thousands-

of-phenotypes-for-337000-samples-in-the-uk-biobank.

15.   Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set

for whole-genome association and population-based linkage analyses. Am J Hum Genet.

2007;81(3):559-75.

16.   Carter AR, Gill D, Davies NM, Taylor AE, Tillmann T, Vaucher J, et al. Understanding the

consequences of education inequality on cardiovascular disease: mendelian randomisation study.

BMJ. 2019;365:l1855.

17.   Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic

analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat

Genet. 2018:50(10):1412-25.

18.   Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample

Mendelian randomization. Genet Epidemiol. 2016;40(7):597-608.

19.   Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000

Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet.

2015;47(10):1121-30.

20.   Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, et al. Genome-wide association

study of peripheral artery disease in the Million Veteran Program. Nat Med. 2019;25(8):1274-9.

21.   Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry

genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and

stroke subtypes. Nat Genet. 2018;50(4):524-37.

22.   Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform

supports systematic causal inference across the human phenome. eLife. 2018;7.

23.   Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, et al. Using

multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med

Res. 2012;21(3):223-42.

24.   Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian

Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet

Epidemiol. 2016;40(4):304-14.

25.   Burgess S, Foley CN, Allara E, Staley JR, Howson JM. A robust and efficient method for

Mendelian randomization with hundreds of genetic variants: unravelling mechanisms linking HDL-

cholesterol and coronary heart disease. bioRxiv. 2019:566851.

26.   Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:

effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-25.

27.   Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal

relationships inferred from Mendelian randomization between complex traits and diseases. Nat

Genet. 2018;50(5):693-8.

28.   Burgess S, Dudbridge F, Thompson SG. Re: "Multivariable Mendelian randomization: the use

of pleiotropic genetic variants to estimate causal effects". Am J Epidemiol. 2015;181(4):290-1.

29.   Carter AR, Sanderson E, Hammerton G, Richmond RC, Smith GD, Heron J, et al. Mendelian

randomisation for mediation analysis: current methods and challenges for implementation. bioRxiv.

2019:835819.

30.   Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic

reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

31.   Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for

trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of

Interventions. Cochrane Database Syst Rev. 2019;10:ED000142.

32.   McMullan CJ, Borgi L, Fisher N, Curhan G, Forman J. Effect of Uric Acid Lowering on Renin-

Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial. Clin J Am Soc

Nephrol. 2017;12(5):807-16.

33.   Omrani H, Muhammad S, Sadeghi K, Raeisi D, Hashemian A. The effect of allopurinol

treatment regimen on serum uric acid and arterial blood pressure in hemodialysis patients. J

Kermanshah Univ Med. 2016;20:56-61.

34.   MacDonald TM, Ford I, Nuki G, Mackenzie IS, De Caterina R, Findlay E, et al. Protocol of the

Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open,

blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the

management of symptomatic hyperuricaemia. BMJ Open. 2014;4(7):e005354.

35.   Mackenzie IS, Ford I, Walker A, Hawkey C, Begg A, Avery A, et al. Multicentre, prospective,

randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving

cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.

BMJ Open. 2016;6(9):e013774.

36.   Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on

exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial.

Lancet. 2010;375(9732):2161-7.

37.   Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-

Egger method. Eur J Epidemiol. 2017;32(5):377-89.

1 Figures

2 Figure 1 - Mendelian randomization estimates for the effect of 1-standard

3 deviation (SD) increase in genetically determined serum urate levels on risk of

4 coronary heart disease (CHD), peripheral artery disease (PAD) and stroke.

CI: confidence interval; Con-Mix: contamination-mixture; IVW: inverse-variance weighted; MVMR:

multivariable Mendelian randomization (adjusting for genetic association of the instrument variants

with body mass index, estimated glomerular filtration rate, type 2 diabetes mellitus, low-density

lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides); OR: odds ratio;

PRESSO: pleiotropy residual sum and outlier. The outlier-corrected PRESSO results are presented (five

outlier variants were identified for CHD, eight for PAD, and one for stroke). The Egger intercept was

1   *0.005 (95% CI 0.001-0.009, P=0.004) for CHD, 0.005 (95% CI 0.001-0.009, P=0.003) for PAD and 0.001*

2   *(95% CI -0.001-0.003, P=0.24) for stroke.*

Figure 2 – Mendelian randomization estimates for the effect of 1-standard

deviation (SD) increase in genetically determined serum urate levels on

systolic blood pressure.

CI: confidence interval; Con-Mix: contamination-mixture; IVW: inverse-variance weighted;

OR: odds ratio; PRESSO: pleiotropy residual sum and outlier. The outlier-corrected PRESSO results are

presented (21 outlier variants were identified). The Egger intercept was 0.002 (95% CI 0.0004-0.003,

8   *P=0.02)*

Figure 3 – Inverse-variance weighted (IVW) and multivariable Mendelian

randomization (MVMR) estimates for the effect of 1-standard deviation (SD)

increase in genetically determined serum urate levels on risk of coronary heart

disease (CHD), peripheral artery disease (PAD) and stroke. The MVMR analysis

adjusts for the association of the genetic instruments with systolic blood

pressure.

CI: confidence interval; OR: odds ratio.

1   **Figure 4 – Forest plot of randomized controlled trial estimates for change in**

2   **mean systolic blood pressure in non-renal dialysis patients receiving urate-**

Study name	Difference in means	Standard error	Variance	Lower limit	Upper limit	Z-Value	p-Value
Alshahawey, 2017	-1.100	4.521	20.441	-9.961	7.761	-0.243	0.808
Gingles, 2019	-0.590	1.886	3.556	-4.286	3.106	-0.313	0.754
Gunawhardana, 2017	-0.300	1.712	2.933	-3.656	3.056	-0.175	0.861
Kimura, 2018	-4.100	0.863	0.744	-5.791	-2.409	-4.753	0.000
McMullan, 2017	-0.900	1.199	1.437	-3.249	1.449	-0.751	0.453
Segal, 2015	-4.200	1.945	3.781	-8.011	-0.389	-2.160	0.031
Higgins, 2014	-7.400	4.380	19.181	-15.984	1.184	-1.690	0.091
Dogan, 2011	3.000	2.688	7.226	-2.269	8.269	1.116	0.264
Kanbay, 2011	-4.300	2.027	4.110	-8.273	-0.327	-2.121	0.034
Goicoechea, 2010	0.000	2.153	4.635	-4.220	4.220	0.000	1.000
Momeni, 2010	-2.200	2.619	6.859	-7.333	2.933	-0.840	0.401
Khan, 2008	-5.600	4.368	19.076	-14.160	2.960	-1.282	0.200
Siu, 2006	-11.000	4.706	22.148	-20.224	-1.776	-2.337	0.019
Morgan, 2018	-7.300	2.828	7.998	-12.843	-1.757	-2.581	0.010
	-2.552	0.767	0.589	-4.056	-1.048	-3.326	0.001

3   **lowering therapy or placebo/no treatment.**

4   *I² heterogeneity statistic: 43%. CI: confidence interval*

1 **Figure 5 – Forest plot of randomized controlled trial estimates for risk of major**

2 **adverse cardiovascular events in all patients receiving urate-lowering therapy**

Study name	Odds ratio	Lower limit	Upper limit	Z-Value	p-Value
Dickerson 2009	2.803	0.110	71.656	0.623	0.533
Givertz 2015	0.685	0.212	2.219	-0.630	0.528
Hare 2008	2.031	0.602	6.854	1.141	0.254
Higgins 2014	0.709	0.148	3.399	-0.429	0.668
Jalal 2016	3.234	0.128	81.791	0.712	0.476
Jarnerot 2000	2.938	0.118	73.033	0.658	0.511
Kamatani 2011 late phase 2	0.706	0.028	17.677	-0.212	0.832
Khan 2008	0.312	0.012	8.285	-0.696	0.486
Mao 2015	0.332	0.013	8.187	-0.674	0.500
NCT01078389 2014	5.064	0.241	106.341	1.044	0.296
NCT01350388 2016	0.325	0.013	8.222	-0.682	0.495
NCT01496469 2015	3.000	0.120	75.113	0.669	0.504
NCT02128490 / Gunawardhana 2016	1.288	0.061	27.378	0.162	0.871
NCT02139046 / Saag 2016	0.998	0.111	8.956	-0.002	0.998
Rentoukas 2010	0.510	0.119	2.188	-0.906	0.365
Saag 2016	0.153	0.015	1.539	-1.594	0.111
Schumacher 2008	1.006	0.052	19.591	0.004	0.997
Separham 2016	0.485	0.086	2.740	-0.819	0.413
Taheraghdam 2014	0.470	0.080	2.749	-0.838	0.402
Zhang 2012	0.265	0.090	0.775	-2.426	0.015
Dalbeth, 2017	1.510	0.249	9.161	0.448	0.654
Huang, 2017	0.235	0.025	2.178	-1.275	0.202
Mukri, 2018	3.061	0.122	76.949	0.680	0.497
Tausche, 2017	3.028	0.122	75.171	0.676	0.499
	0.725	0.482	1.091	-1.541	0.123

Odds ratio and 95% CI

0.01 0.1 1 10 100

Favours Urate Lowering   Favours Control

3 **or placebo/no treatment.**

4 *I² heterogeneity statistic: 0%. CI: confidence interval.*

1 **Figure 6 – Forest plot of randomized controlled trial estimates for risk of major**

2 **adverse cardiovascular events in patients with existing cardiovascular disease**

Study name	Statistics for each study					Odds ratio and 95% CI
	Odds ratio	Lower limit	Upper limit	Z-Value	p-Value	
Higgins 2014	0.709	0.148	3.399	-0.429	0.668	
Khan 2008	0.312	0.012	8.285	-0.696	0.486	
Rentoukas 2010	0.510	0.119	2.188	-0.906	0.365	
Separham 2016	0.485	0.086	2.740	-0.819	0.413	
Taheraghdam 2014	0.470	0.080	2.749	-0.838	0.402	
Zhang 2012	0.265	0.090	0.775	-2.426	0.015	
Huang, 2017	0.235	0.025	2.178	-1.275	0.202	
	0.396	0.216	0.729	-2.977	0.003	

0.01　0.1　1　10

Favours Urate Lowering　　Favours Control

3 **receiving urate-lowering therapy or placebo/no treatment.**

4 *I² heterogeneity statistic: 0%. CI: confidence interval.*